What is it?
What SR9009 is
2SR9009 is a synthetic Rev-erb agonist also sold online as Stenabolic. It is often grouped with SARMs in supplement markets, but mechanistically it is better described as a Rev-erb/circadian-metabolic modulator, not a selective androgen receptor modulator.
Preclinical evidence dominates
2The key SR9009 literature examines REV-ERB pharmacology, circadian behavior, metabolism, sleep/wake regulation, neural precursor-cell biology, and analog design in non-human systems. Those findings are useful for mechanism review, but they do not establish consumer outcomes.
Names, aliases and forms
Mechanisms of action
Rev-erb agonism links circadian and metabolic biology
2REV-ERB-alpha and REV-ERB-beta are nuclear receptors tied to circadian transcription and metabolism. SR9009 is used in research to probe those pathways, which is why sleep/wake, glucose/lipid, liver, activity, and endocrine-adjacent cautions matter.
Off-target findings weaken simple mechanism claims
5A PNAS paper reported REV-ERB-independent effects of SR9009 on cell proliferation and metabolism. That does not prove a specific human harm, but it means vendor explanations that present SR9009 as a clean, predictable Rev-erb switch are too simple.
Potential effects and evidence map
SR9009 evidence is preclinical. The key Nature paper introduced synthetic REV-ERB agonists including SR9009 and reported effects on circadian behavior and metabolism in experimental models. Later mouse work examined sleep/wake regulation and Rev-erb beta dependence, while cell work reported concentration-dependent neural precursor effects and a PNAS paper warned that SR9009 can have REV-ERB-independent effects on cell proliferation and metabolism. ClinicalTrials.gov searches for SR9009, SR 9009, and Stenabolic returned no human studies suitable for nootropic efficacy, dose, onset, or safety claims.
Mouse sleep/wake findings do not establish a safe or reliable human wakefulness, energy, or productivity effect.
Exercise and metabolic claims remain preclinical and analog-heavy, with no human SR9009 endurance validation.
Typical dosages and timing
Do not convert mouse injections, cell concentrations, analog studies, vendor labels, or forum cycles into a human SR9009 dose. No public supplement dose, cycle length, monitoring plan, or safety boundary was found.
Timing & effect horizon
Safety, side effects and risk profile
For WADA-code athletes, SR9009 is among the named S4.4.1 Rev-erbα agonists, prohibited both in and out of competition.
No human nootropic efficacy, dose, onset, duration, or long-term safety evidence was found.
SR9009 affects sleep/wake biology in animal models, so circadian disruption, insomnia, and wakefulness effects are plausible concerns rather than proven benefits.
Circadian, metabolic, endocrine, glucose/lipid, sleep, psychiatric, and medication contexts create high uncertainty for unsupervised use.
Pregnancy, attempts to conceive, lactation, adolescence, and fertility-sensitive contexts are inappropriate for unsupervised SR9009 exposure.
Human cardiovascular effects are unknown, and a compound that targets circadian-metabolic nuclear-receptor biology should not be assumed cardiovascular-neutral.
People with sleep disorders, bipolar-spectrum symptoms, anxiety, cardiovascular disease, diabetes, liver disease, endocrine disorders, pregnancy, lactation, fertility concerns, or complex medication regimens should avoid unsupervised SR9009 exposure.
Legal and regulatory status
The 2026 WADA Prohibited List puts Rev-erbα agonists—examples include SR9009 and SR9011—in S4.4.1, an all-times prohibition for WADA-code sport. USADA also identifies SR9009/Stenabolic as prohibited and cautions that it may be marketed as a SARM. General consumer legality still depends on country, product, seller, and use case.
Practical buying and quality notes
- If a listing presents SR9009 as a SARM, fat-loss shortcut, endurance shortcut, or clean stimulant, the label is already blurring basic identity and evidence. Verify independent analytical testing, batch identity, and legal/sport risk before comparing price.9
- Product rows and price links can document market availability, but they should not be read as a recommendation to buy or use SR9009. The anti-doping, evidence, purity, and safety sections should be read first.10
FAQ
Is SR9009 a SARM?
10No. It is often marketed near SARMs, but SR9009 is a synthetic Rev-erb agonist and metabolic modulator, not a selective androgen receptor modulator.
Is SR9009 a reliable nootropic supplement?
8No. No human evidence was found for reliable focus, memory, mood, productivity, or healthy-user cognitive benefits.
What SR9009 dose is established?
8No public human supplement dose is established. Animal, cell, vendor, and forum numbers should not be converted into a self-use plan.
Is SR9009 banned in sport?
10Yes in WADA-code sport. SR9009 is covered by the S4 category for Rev-erb agonists, which applies at all times.
Why mention off-target effects?
5Because SR9009 is often sold with simple Rev-erb marketing claims. Published cell work reports REV-ERB-independent effects, so the mechanism should be described as uncertain rather than clean or predictable.
References
- PubChem. SR9009, CID 57394020. Accessed 2026-06-30.
- Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62-68.
- Banerjee S, Wang Y, Solt LA, et al. Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation. PLoS One. 2016;11(9):e0162452.
- Doi M, Murai I, Kunisue S, et al. REV-ERBbeta is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009. Biochemical Pharmacology. 2018;150:1-8.
- Dierickx P, Emmett MJ, Jiang C, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proceedings of the National Academy of Sciences. 2019;116(25):12147-12152.
- Morioka N, Abe H, Saeki M, et al. REV-ERB Agonist SR9009 Regulates the Proliferation and Neurite Outgrowth/Suppression of Cultured Rat Adult Hippocampal Neural Stem/Progenitor Cells in a Concentration-Dependent Manner. Cellular and Molecular Neurobiology. 2022;42:1907-1920.
- Zhu Y, et al. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-alpha agonists. Bioorganic & Medicinal Chemistry. 2024;106:117845.
- ClinicalTrials.gov search results for SR9009, SR 9009, and Stenabolic. Accessed 2026-06-30.
- U.S. Anti-Doping Agency. Selective Androgen Receptor Modulators (SARMs). Accessed 2026-06-30.
- World Anti-Doping Agency. The 2026 Prohibited List: International Standard. Version effective 1 January 2026.